Literature DB >> 24769842

Decreased expression of NKG2D, NKp46, DNAM-1 receptors, and intracellular perforin and STAT-1 effector molecules in NK cells and their dim and bright subsets in metastatic melanoma patients.

Katarina M Mirjačić Martinović1, Nada Lj Babović, Radan R Džodić, Vladimir B Jurišić, Nikola T Tanić, Gordana M Konjević.   

Abstract

Although natural killer (NK) cells play an important antitumor role, melanoma cells may affect their effector functions. In this study, we analyzed the expression of various receptors and effector molecules in NK cells and their subsets in metastatic melanoma (MM) patients compared with healthy controls (HCs). In HC and MM patients, we analyzed NK cell activity using a chromium release assay and the expression of CD107a degranulation marker, activating NKG2D, NKp46, DNAM-1, and inhibitory CD158a and CD158b receptors, IL-12R beta 1, IL-12R beta 2, intracellular interferon (IFN)-γ, perforin, and STAT-1 in CD3-CD56+ NK cells, and cytotoxic CD3-CD56 and immunoregulatory CD3-CD56 subsets by flow cytometry. MM patients compared with HC not only had significantly decreased NK cell activity, lower expression of CD107a, and impaired IFN-γ production but also had decreased expression of activating NKG2D, NKp46, and DNAM-1 receptors, which was followed by lower expression of perforin, STAT-1, and both IL-12R subunits in NK cells. In MM patients only, there was a positive correlation between NKG2D expression and degranulation capacity, as well as IFN-γ production in NK cells. Analysis of the expression of various parameters of NK cell effector functions between MM patients with different localization of distant metastases showed that patients in the unfavorable M1c subclass had decreased expression of NKG2D and NKp46 on NK cells compared with patients in the M1a+b group. Downregulated NKG2D, NKp46, and DNAM-1 receptors associated with impaired NK cell effector function are important biomarkers of advanced disease with a poor prognosis in melanoma patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24769842     DOI: 10.1097/CMR.0000000000000072

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  16 in total

Review 1.  Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma.

Authors:  Nicolas Jacquelot; Jonathan M Pitt; David P Enot; Maria Paula Roberti; Connie P M Duong; Sylvie Rusakiewicz; Alexander M Eggermont; Laurence Zitvogel
Journal:  Oncoimmunology       Date:  2017-03-07       Impact factor: 8.110

Review 2.  Natural killer cell receptors: alterations and therapeutic targeting in malignancies.

Authors:  Gordana Konjević; Ana Vuletić; Katarina Mirjačić Martinović
Journal:  Immunol Res       Date:  2016-02       Impact factor: 2.829

Review 3.  Critical roles of co-activation receptor DNAX accessory molecule-1 in natural killer cell immunity.

Authors:  Peng Xiong; Hai-Wei Sang; Min Zhu
Journal:  Immunology       Date:  2015-09-28       Impact factor: 7.397

4.  Favorable in vitro effects of combined IL-12 and IL-18 treatment on NK cell cytotoxicity and CD25 receptor expression in metastatic melanoma patients.

Authors:  Katarina Mirjačić Martinović; Nada Babović; Radan Džodić; Vladimir Jurišić; Suzana Matković; Gordana Konjević
Journal:  J Transl Med       Date:  2015-04-14       Impact factor: 5.531

5.  A role for pre-mNK cells in tumor progression.

Authors:  Carolyn Rosinsky; Paul Andrew Antony
Journal:  J Immunother Cancer       Date:  2016-03-15       Impact factor: 13.751

6.  Novel Strategy to Expand Super-Charged NK Cells with Significant Potential to Lyse and Differentiate Cancer Stem Cells: Differences in NK Expansion and Function between Healthy and Cancer Patients.

Authors:  Kawaljit Kaur; Jessica Cook; So-Hyun Park; Paytsar Topchyan; Anna Kozlowska; Nick Ohanian; Changge Fang; Ichiro Nishimura; Anahid Jewett
Journal:  Front Immunol       Date:  2017-04-05       Impact factor: 7.561

7.  Natural Killer Group 2D Ligand Depletion Reconstitutes Natural Killer Cell Immunosurveillance of Head and Neck Squamous Cell Carcinoma.

Authors:  Sandra Weil; Stefanie Memmer; Axel Lechner; Volker Huppert; Ariane Giannattasio; Tamara Becker; Andreas Müller-Runte; Karen Lampe; Dirk Beutner; Alexander Quaas; Ralf Schubert; Eva Herrmann; Alexander Steinle; Ulrike Koehl; Lutz Walter; Michael S von Bergwelt-Baildon; Joachim Koch
Journal:  Front Immunol       Date:  2017-04-10       Impact factor: 7.561

8.  Memory-like Differentiation Enhances NK Cell Responses to Melanoma.

Authors:  Nancy D Marin; Bradley A Krasnick; Michelle Becker-Hapak; Leah Conant; Simon P Goedegebuure; Melissa M Berrien-Elliott; Keenan J Robbins; Jennifer A Foltz; Mark Foster; Pamela Wong; Celia C Cubitt; Jennifer Tran; Christopher B Wetzel; Miriam Jacobs; Alice Y Zhou; David Russler-Germain; Lynne Marsala; Timothy Schappe; Ryan C Fields; Todd A Fehniger
Journal:  Clin Cancer Res       Date:  2021-06-29       Impact factor: 12.531

Review 9.  Natural Killer Cell Recognition of Melanoma: New Clues for a More Effective Immunotherapy.

Authors:  Raquel Tarazona; Esther Duran; Rafael Solana
Journal:  Front Immunol       Date:  2016-01-07       Impact factor: 7.561

10.  Efficacy of Juzentaihoto for Tumor Immunotherapy in B16 Melanoma Metastasis Model.

Authors:  Shintaro Ishikawa; Takako Ishikawa; Chiaki Tezuka; Kazuhito Asano; Masataka Sunagawa; Tadashi Hisamitsu
Journal:  Evid Based Complement Alternat Med       Date:  2017-02-12       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.